Cancer-testis Antigen Expression in Triple-negative Breast Cancer

Overview

Journal Ann Oncol

Publisher Elsevier

Specialty Oncology

Date 2010 Jul 9

PMID 20610479

Citations 54

Authors

G Curigliano

G Viale

M Ghioni

A A Jungbluth

V Bagnardi

G C Spagnoli

A M Neville

F Nole

N Rotmensz

A Goldhirsch

Affiliations

Soon will be listed here.

Abstract

Background: cancer-testis (CT) antigens, frequently expressed in human germline cells but not in somatic tissues, may become aberrantly reexpressed in different cancer types. The aim of this study was to investigate the expression of CT antigens in breast cancer.

Patients And Methods: a total of 100 selected invasive breast cancers, including 50 estrogen receptor (ER) positive/HER2 negative and 50 triple negative (TN), were examined for NY-ESO-1 and MAGE-A expression by immunohistochemistry.

Results: a significantly higher expression of MAGE-A and NY-ESO-1 was detected in TN breast cancers compared with ER-positive tumors (P = 0.04). MAGE-A expression was detected in 13 (26%) TN cancers compared with 5 (10%) ER-positive tumors (P = 0.07). NY-ESO-1 expression was confirmed in nine (18%) TN tumor samples compared with two (4%) ER-positive tumors.

Conclusions: MAGE-A and NY-ESO-1 CT antigens are expressed in a substantial proportion of TN breast cancers. Because of the limited therapeutic options for this group of patients, CT antigen-based vaccines might prove to be useful for patients with this phenotype of breast cancer.

Citing Articles

Evaluation of MAGE-A4 expression in breast cancer and its impact on prognosis.

Nakamura K, Saito K, Higashi C, Kozuka Y, Yuasa H, Nishimura Y Cancer Sci. 2024; 116(3):744-752.

PMID: 39704015 PMC: 11875791. DOI: 10.1111/cas.16433.

NY-ESO-1 antigen: A promising frontier in cancer immunotherapy.

Alsalloum A, Shevchenko J, Sennikov S Clin Transl Med. 2024; 14(9):e70020.

PMID: 39275923 PMC: 11399778. DOI: 10.1002/ctm2.70020.

Gene and Protein Expression of MAGE and Associated Immune Landscape Elements in Non-Small-Cell Lung Carcinoma and Urothelial Carcinomas.

Faiena I, Adhikary S, Schweitzer C, Astrow S, Grogan T, Funt S J Immunother. 2024; 47(9):351-360.

PMID: 39169899 PMC: 11446647. DOI: 10.1097/CJI.0000000000000538.

Drug Delivery Opportunities in Esophageal Cancer: Current Treatments and Future Prospects.

Sabatelle R, Colson Y, Sachdeva U, Grinstaff M Mol Pharm. 2024; 21(7):3103-3120.

PMID: 38888089 PMC: 11331583. DOI: 10.1021/acs.molpharmaceut.4c00246.

Prognostic Value of "Basal-like" Morphology, Tumor-Infiltrating Lymphocytes and Multi-MAGE-A Expression in Triple-Negative Breast Cancer.

ceprnja T, Tomic S, Peric Balja M, Marusic Z, Blazicevic V, Spagnoli G Int J Mol Sci. 2024; 25(8).

PMID: 38674098 PMC: 11050590. DOI: 10.3390/ijms25084513.